14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
BCAX vs DAWN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DAWN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–2 Matrix Metrics)
DAWN Overall Winner
6-Pillar Tally: BCAX 1 – 4 DAWN (1 Tie)
Matrix Metrics: BCAX 2 – 6 DAWN
As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas DAWN carries 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin).
Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs DAWN. Trailing 12-month operating profitability (BCAX 0.0% vs DAWN -51.1%) and valuation multiples (BCAX N/M vs DAWN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $665.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
DAWN Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2B market capitalization and -51.1% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ BCAX vs DAWN Key Questions & Quantitative Answers
As of Nov 16, 2026, Day One Biopharmaceuticals, Inc. (DAWN) is the stronger overall head-to-head candidate over Bicara Therapeutics Inc. (BCAX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). BCAX carries a Unified Composite Score of 52.1/100 (HOLD) at $9.75 (N/M Forward P/E, 0.0% operating margin), whereas DAWN carries 58.3/100 (HOLD) at $21.53 (N/M Forward P/E, -51.1% operating margin). Technical & Structure Timing Caution: BCAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 32.7); meanwhile DAWN trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 80.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
DAWN leads the Growth & Scale pillar: BCAX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DAWN at +83.9% YoY revenue growth and +0.0% YoY earnings growth on $158M TTM revenue (89.1% gross margin, -51.1% operating margin). On trailing 12-month operating scale, BCAX generates N/A in USD-normalized revenue versus $158M for DAWN. In operating R&D and SG&A reinvestment, BCAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DAWN.
DAWN screens cheaper on headline valuation multiples. BCAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DAWN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.0x EV/Revenue (-78.6% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BCAX (-54.2% ROE) versus DAWN (-22.7% ROE) capital efficiency.
In options market volatility and institutional positioning, BCAX carries 102.7% implied volatility (23rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.42β · 184% Vol realized risk). By comparison, DAWN carries 0.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.45x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.03β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.